中风与神经疾病杂志2024，Vol.41Issue(7)：604-610,7.DOI:10.19845/j.cnki.zfysjjbzz.2024.0118
降钙素基因相关肽类药物治疗偏头痛的研究进展
Research advances in calcitonin gene-related peptides in treatment of migraine
摘要
Abstract
Migraine is a common type of primary headache worldwide,and its high morbidity and disability rates have brought heavy burden to individuals and society,thereby requiring preventive and acute treatment.Previous thera-peutic strategies for migraine include traditional analgesics and triptans,which are mainly used to relieve pain and reduce accompanying symptoms,but long-term administration of such drugs may lead to medication overuse headache.In recent years,new drugs targeting calcitonin gene-related peptide(CGRP)and its receptors have shown a promising future in the preventive treatment of migraine and the treatment of migraine in the acute stage,such as monoclonal antibodies and small-molecular receptor antagonists,and in addition,they also can be used in patients who have no response to various pharma-cotherapies.This article reviews the recent advances in CGRP drugs in the treatment of migraine.关键词
降钙素基因相关肽/偏头痛/CGRP单克隆抗体/CGRP受体拮抗剂/临床试验Key words
Calcitonin gene-related peptide/Migraine/Monoclonal antibodies/Small-molecular receptor antagonists/Clinical trial分类
医药卫生引用本文复制引用
韩卓,万东君,马丹丹..降钙素基因相关肽类药物治疗偏头痛的研究进展[J].中风与神经疾病杂志,2024,41(7):604-610,7.基金项目
甘肃省自然科学基金(21JR1RA187) （21JR1RA187）
